No Difference Between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients With Symptomatic Celiac Disease

Autor: Ansari, S., Ayub, K., Basile, A., Behrend, C., Bercik, P., Bressler, B., Byrnes, V., Chandan, V.S., Cheekati, V., Chipps, B., Coates, A., Collatrella, A., Condemi, J., Corder, C., Corren, J., Curtis, C., DeMeo, M., Desta, T., Devereaux, C., DiMarino, A., DuPree, M., Ennis, C., Fedorak, R., Fogel, R., Freeman, S., Freilich, B., Friedenberg, K., Geenen, D., Gill, K., Goldsobel, A., Goldstein, J., Goldstein, M., Gordon, G., Hardi, R., Harris, L., Holmes, R., Jagarlamundi, K., James, G., Kaplan, M., Kirstein, J., Knoll, A., Kotfila, R., Krause, R., Kravitz, A., Kreines, M., Lähdeaho, M.L., Lamet, M., Laskin, K., Lebwohl, B., Leffler, D., Lewis, S., Liakos, S., Lundin, K., Marks, K., Merkes, K., Minton, S., Moussa, S., Narayen, V., Nehra, V., Newton, E., Nyberg, A., Oosthuizen, J., Otrok, T., Patel, D., Pepin, C., Phillips, R., Pyle, G., Reichelderfer, M., Reid, B., Ritter, T., Saini, S., Sanders, D., Schulman, M., Semrad, C., Shah, S., Stockwell, D., Strout, C., Suez, D., Tatum, H., Torbenson, M.S., Turner, M., Varunok, P., Vazquez-Roque, M., Vento, A., Welton, T., Wohlman, R., Wood, M., Woods, S., Yousef, K., Murray, Joseph A., Kelly, Ciarán P., Green, Peter H.R., Marcantonio, Annette, Wu, Tsung-Teh, Mäki, Markku, Adelman, Daniel C.

Publikováno v: In Gastroenterology March 2017 152(4):787-798

Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial

Autor: Rodbard, HW, Rosenstock, J, Canani, LH, Deerochanawong, C, Gumprecht, J5, Lindberg, SØ, Lingvay, I, Søndergaard, AL, Treppendahl, MB, Montanya, E, Cruz, P, Loredo, L, Luquez, C, Moisello, M, Augusto, GA, Castro, M, Canani, L, Akrap, Branko, Bulum, Tomislav, Rahelić, Dario, Šunić-Grčić, Ivana, Tušek, Srećko, Avramidis, I, Benroubi, M, Didangelos, T, Karousos, G, Pagkalos, E, Sampanis, C, Somali, M, Domboróczki, Z, Faludi, P, Gaál, Z, Kis- Gombos, P, Kocsis, G, Marton, Z, Sudár, Z, Buscemi, S, Di Carlo, A, Dotta, F, Gambineri, A, Lauro, D, Maranghi, M, Arciszewska, M, Gumprecht, J, Matuszewska, K, Skokowska, E, Stasinska, T, Feofanova, S, Filippova, E, Galstyan, G, Gaysina, L, Kunitsyna, M, Suplotova, L, Antic, S, Djukic, A, Mitrovic, M, Pesic, M, Stokic, E, Jodar, E, Martínez, E, Raya, PM, Portillo, CM, Vera, MP, Fernández, MR, San Jose, P, Riera, MT, Boonyavarakul, A, Sriwijitkamol, A, Ajani, D, Armas, E, Barbel- Johnson, K, Bartilucci, D, Bonabi, G, Busch, R, Butuk, D, Cannon, K, Chase, C, Chaykin, L, Cheekati, V, Davis, T, Delgado, B, Farris, N, Graves, M, Ha, C, Harper, L, Herring, S, Hewitt, M, Hsia, D, Jackson, R, Jardula, M, Joyce, M, Juarez, M, Kapoor, A, Karounos, D, Kayne, D, Lacour, A, Ledesma, G, Lipetz, R, Lomboy, J, Lynd, S, Morawski, E, Morin, R, Murphy, R, Overcash, JS, Pullman, J, Ruoff, G, Steenkamp, D, Toro, H, Trachtenbarg, D, Tulloch, B, Weisbrot, A, Wright, A.

OBJECTIVE Efficacy and safety of the glucagon-like peptide 1 (GLP-1) analog oral semaglutide and the sodium–glucose cotransporter 2 inhibitor empagliflozin were compared in patients with type 2 diabetes uncontrolled on metformin. RESEARCH DESIGN AN

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11d426d2138bca66de639b58bfb9884d
https://doi.org/10.2337/dc19-0883

Insulin therapy for inpatients with diabetes: perceptions of resident physicians from disparate geographic training programs.

Autor: Cheekati V, Osburne RC, Jameson KA, Cook CB

Publikováno v: Insulin; Apr2009, Vol. 4 Issue 2, p106-113, 8p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.